Abzena Bulks up R&D Services to Include B Cell Discovery Tech
CDMO boosts capabilities at Cambridge location
Abzena, a contract development and manufacturing organization (CDMO) that provides integrated discovery, development, and manufacturing of biologics and antibody drug conjugates (ADCs), has upgraded to its research and development capabilities in Cambridge, UK. This features an investment in B cell discovery technologies.
As part of its investment in primary B cell antibody discovery technologies, the CDMO has implemented the Berkley Lights’ Beacon system, its branded platform that supports rapid antibody discovery, by isolating single B cells from a target-primed cohort of lymphocytes. According to the company, the technology enhances the capabilities of its R&D team in antibody discovery, enabling delivery of recombinant antibodies, in a shorter time span.
“The introduction of B cell discovery to Abzena’s capabilities is a significant new advancement to our antibody offering and is part of a number of new developments in the pipeline for Abzena,” says Campbell Bunce, the company’s chief scientific officer.
